Monday, December 22, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Stocks

Genmab Stock: Breakthrough Therapy Sparks 5% Surge

Felix Baarz by Felix Baarz
August 7, 2025
in Stocks
0
Genmab Stock
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

Danish biotech firm Genmab saw its shares jump over 5% to $22.70 after announcing groundbreaking Phase 3 trial results for its lymphoma therapy. The EPCORE FL-1 study showed a 79% reduction in disease progression or death risk for patients with relapsed follicular lymphoma when treated with Epcoritamab combined with Rituximab and Lenalidomide. Both primary endpoints were met, with a remarkable 95.7% response rate. The U.S. FDA has granted accelerated review, with approval expected by November 30, potentially making this the first bispecific antibody combo for second-line treatment of the disease in the U.S.

Financial Momentum and Pipeline Strength

Genmab’s revenue grew 19% to $1.64 billion in H1 2025, driven by blockbuster drugs DARZALEX and Kesimpta. Operating profit nearly doubled to $548 million, prompting raised full-year guidance. Beyond Epcoritamab, the company is advancing Rinatabart sesutecan for endometrial cancer, bolstering its oncology portfolio. A strategic partnership with a major pharma firm enhances global commercialization prospects, positioning Genmab as a key player in innovative cancer therapies.

Ad

Genmab Stock: Buy or Sell?! New Genmab Analysis from December 22 delivers the answer:

The latest Genmab figures speak for themselves: Urgent action needed for Genmab investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 22.

Genmab: Buy or sell? Read more here...

Tags: Genmab
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Eli Lilly Stock
Stocks

Eli Lilly’s Strategic Diversification Amid Weight-Loss Drug Competition

November 18, 2025
Micron Stock
Stocks

Micron Shares Approach Peak: What Comes After the AI Rally?

November 18, 2025
Varonis Stock
Stocks

Varonis Shares Plunge Amidst Mixed Signals

November 18, 2025
Next Post
Datadog Stock

Datadog Stock: Soars on Strong Earnings and AI Boom

Eli Lilly Stock

Eli Lilly Stock: Surging on Indian Demand and Market Dominance

Yandex Stock

Yandex Stock: Cloud Specialist Nebius Soars on Record Growth

Recommended

Redfin Stock

Navigating Market Turbulence: Redfin’s Challenging Real Estate Landscape

3 months ago
MercadoLibre Stock

MercadoLibre’s Strategic Expansion into Brazil’s Pharmaceutical Sector

2 months ago
Orsted Stock

Orsted Stock: Crisis Deepens as $8.8B Rescue Plan Unveiled

4 months ago
Staar Surgical Stock

Boardroom Battle Erupts at Staar Surgical Ahead of Crucial Vote

3 weeks ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Bitcoin Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Fiserv Stock: A Potential Rebound Amidst Institutional Accumulation?

Solana’s Contradiction: Institutional Faith Meets Network Strain

PepsiCo’s Strategic Pivot Meets Investor Skepticism

Adobe Faces Mounting Challenges Despite Strong Earnings

Jabil Shares Surge on Upbeat Guidance and Robust Quarterly Performance

Rolls-Royce Charts Course for Shareholder Returns with New Financial Framework

Trending

LVMH Stock
Analysis

LVMH Shares: A Market in Search of Equilibrium

by Felix Baarz
December 22, 2025
0

The era of unchecked expansion in the global luxury sector appears to be transitioning into a period...

Vulcan Energy Stock

Vulcan Energy Shares Gain Analyst Favor Following Project Milestone

December 22, 2025
Pfizer Stock

Pfizer’s 2026 Midpoint: A Stock Under Pressure Amid Strategic Pivots

December 22, 2025
Fiserv Stock

Fiserv Stock: A Potential Rebound Amidst Institutional Accumulation?

December 22, 2025
Solana Stock

Solana’s Contradiction: Institutional Faith Meets Network Strain

December 22, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • LVMH Shares: A Market in Search of Equilibrium
  • Vulcan Energy Shares Gain Analyst Favor Following Project Milestone
  • Pfizer’s 2026 Midpoint: A Stock Under Pressure Amid Strategic Pivots

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com